CK 0804
Alternative Names: CK-0804; CK-08041Latest Information Update: 13 Jul 2024
At a glance
- Originator Cellenkos
- Class Antineoplastics; Immunotherapies; Regulatory T lymphocyte cell therapies; T lymphocyte cell therapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Myelofibrosis
Most Recent Events
- 31 May 2024 Efficacy and adverse events data from a phase Ib trial in Myelofibrosis presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 01 Apr 2024 Cellenkos enters into sponsored research agreement with Icahn School of Medicine for CK 0804 for Myelofibrosis
- 09 Dec 2023 Efficacy and adverse event data from a phase Ib TREG108 trial in Myelofibrosis presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)